<SEC-DOCUMENT>0001193125-21-055687.txt : 20210225
<SEC-HEADER>0001193125-21-055687.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225070754
ACCESSION NUMBER:		0001193125-21-055687
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210225
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moderna, Inc.
		CENTRAL INDEX KEY:			0001682852
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				813467528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38753
		FILM NUMBER:		21676373

	BUSINESS ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6177146500

	MAIL ADDRESS:	
		STREET 1:		200 TECHNOLOGY SQUARE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Moderna Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160822
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d118084d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrna="http://www.modernatx.com/20210225" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-02-25_to_2021-02-25">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-02-25_to_2021-02-25">0001682852</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="mrna-20210225.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-02-25_to_2021-02-25"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682852</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-02-25</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-02-25_to_2021-02-25">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-02-25_to_2021-02-25" format="ixt:datemonthdayyearen">February 25, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-02-25_to_2021-02-25">MODERNA, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-02-25_to_2021-02-25" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-02-25_to_2021-02-25">001-38753</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-02-25_to_2021-02-25">81-3467528</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-02-25_to_2021-02-25">200 Technology Square</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-02-25_to_2021-02-25">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-02-25_to_2021-02-25">MA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-02-25_to_2021-02-25">02139</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code): <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-02-25_to_2021-02-25">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-02-25_to_2021-02-25">714-6500</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-02-25_to_2021-02-25" format="ixt-sec:boolballotbox"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-02-25_to_2021-02-25" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-02-25_to_2021-02-25" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-02-25_to_2021-02-25" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-02-25_to_2021-02-25" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-02-25_to_2021-02-25">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-02-25_to_2021-02-25">MRNA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-02-25_to_2021-02-25" format="ixt-sec:exchnameen">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;&#9744;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&#160;25, 2021, Moderna, Inc. (the &#8220;Company&#8221;) issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December&#160;31, 2020. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Current Report on Form <span style="white-space:nowrap">8-K</span> and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d118084dex991.htm">Press release issued by Moderna, Inc. dated February&#160;25, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: February&#160;25, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">MODERNA, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David W. Meline</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">David W. Meline</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d118084dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I><B><I>2021 Vaccine Manufacturing:</I></B><I> Raises lower end of global manufacturing plan for 2021 from 600&nbsp;million doses to
700&nbsp;million doses; manufacturing is still working to supply up to 1&nbsp;billion doses for 2021 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I><B><I>2022 Vaccine
Manufacturing:</I></B><I> Based on the high demand from around the world for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine and variant-based boosters, making new capital investments to increase capacity up to 1.4&nbsp;billion doses in
2022 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I><B><I>Commercial Subsidiaries:</I></B><I> Company established 8 commercial subsidiaries in 2020 in North America and
Europe and plans to expand in 2021 to Japan, South Korea and Australia </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CAMBRIDGE, Mass., February</B><B></B><B>&nbsp;25,
2021</B><B></B>&nbsp;&#151; Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,&nbsp;today reported financial results and provided business updates for the fourth quarter and fiscal year
2020 and highlighted pipeline progress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;2020 was a historic year for Moderna. The team rose to the challenge to address the devastating <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic in less than one year with our authorized vaccine. It is encouraging and humbling that more than 32&nbsp;million doses of our vaccine have been administered in the U.S. and that millions of people
around the world have been vaccinated with our vaccine to date. 2020 demonstrated the power of harnessing mRNA to make medicines and demonstrated the speed and scalability of the Moderna platform that we have built over the last 10 years,&#148; said
St&eacute;phane Bancel, Chief Executive Officer of Moderna. &#147;I believe that 2021 will be an inflection year for Moderna. We previously believed that mRNA would lead to approved medicines, and we were limited in our ambitions by the need for
regular capital raises and keeping several years of cash to manage financing risk. We now know that mRNA vaccines can be highly efficacious and authorized for use, and we are a cash-flow generating commercial company. We opened commercial
subsidiaries in 8 countries in 2020 and plan to add Japan, South Korea and Australia in 2021. We plan to accelerate and significantly increase our investments in science and grow our development pipeline faster. By executing on our 2021 priorities,
we will advance our mission of delivering on the promise of mRNA science to create a new generation of transformative medicines for patients. This is just the beginning.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New updates and recent progress include: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Development </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Raises lower end of global manufacturing plan for 2021 from 600&nbsp;million doses to 700&nbsp;million doses;
making capital investments to increase capacity up to an expected 1.4&nbsp;billion doses in 2022 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2/3 study of mRNA-1273 in adolescents has completed enrollment of 3,000 participants </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Infectious Diseases </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First cohort in the Phase 1 study of hMPV/PIV3 vaccine candidate (mRNA-1653) fully enrolled
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First older adult in the Phase 1 study of RSV vaccine candidate (mRNA-1345) has been dosed </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">First 3 cohorts in age <FONT STYLE="white-space:nowrap">de-escalation</FONT> study of RSV vaccine candidate
(mRNA-1345) for the pediatric population fully enrolled </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rare Diseases </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Study <FONT STYLE="white-space:nowrap">start-up</FONT> activities for Phase 1/2 study of PA candidate (mRNA-3927)
ongoing </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cardiovascular Diseases </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regained all rights to the Relaxin development candidate from AstraZeneca </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna currently has 24 mRNA development programs in its portfolio with 13 having entered clinical studies.
The Company&#146;s updated pipeline can be found at <U>www.modernatx.com/pipeline</U>. Moderna and collaborators have published more than 65 peer-reviewed papers. <B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Program Highlights by Modality</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Core
Modalities</B> <B><I> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prophylactic Vaccines:</I></B><B><I></I></B><I>&nbsp;Moderna</I><I></I><I>&nbsp;is developing vaccines against viral
diseases where there is unmet medical need &#150; including complex vaccines with multiple antigens for common diseases, as well as vaccines against threats to global public health. The Company&#146;s global public health portfolio is focused on
epidemic and pandemic diseases for which funding has been sought from governments and <FONT STYLE="white-space:nowrap">non-profit</FONT> organizations.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Development </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine:</B> On&nbsp;December 30, 2020, interim
safety and primary efficacy&nbsp;results&nbsp;from the Phase 3 trial of the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine (mRNA-1273) were published in the<I>&nbsp;New England Journal of Medicine</I>. Safety data continues to
accrue, and the study continues to be monitored by an independent Data Safety Monitoring Board (DSMB) appointed by the&nbsp;National Institutes of Health (NIH). All participants in the COVE study will be monitored for two years after their second
dose to assess long-term protection and safety. Today, the Company is sharing an update on the Phase 3 COVE study. An updated total of adjudicated <FONT STYLE="white-space:nowrap">COVID-19</FONT> cases among baseline seronegative participants in the
COVE study starting two weeks following the second dose showed 690 cases to date, of which 639 cases of <FONT STYLE="white-space:nowrap">COVID-19</FONT> were observed in the placebo group versus 51 cases observed in the Moderna <FONT
STYLE="white-space:nowrap">COVID-19</FONT> Vaccine group. Participants in the Phase 3 COVE study are in the process of being unblinded and cases will continue to accrue. On&nbsp;December 18, 2020, the&nbsp;U.S. Food and Drug Administration (FDA)
authorized&nbsp;the emergency use of mRNA-1273, Moderna&#146;s vaccine against <FONT STYLE="white-space:nowrap">COVID-19,</FONT> in individuals 18 years of age and older. Moderna&nbsp;has also received emergency (or other conditional, interim or
provisional) authorization for use of its <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine from health agencies in&nbsp;Canada,&nbsp;Israel, the&nbsp;European Union, the&nbsp;United Kingdom,&nbsp;Switzerland, Singapore and Qatar.
Moderna&nbsp;is working with additional health agencies and with the&nbsp;World Health Organization&nbsp;on the authorization of its vaccine in additional jurisdictions. BARDA, part of the&nbsp;Office of the Assistant Secretary for Preparedness and
Response (ASPR) within the&nbsp;U.S. Department of Health and Human Services&nbsp;(HHS), partially supported the research and development of the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine with federal funding under Contract no.
75A50120C00034. Moderna&nbsp;retains worldwide rights to develop and commercialize the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Addressing Variants of Concern: </B>On February&nbsp;24, Moderna announced that it completed manufacturing of
clinical trial material for its variant-specific vaccine candidate, mRNA-1273.351, against the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variant known as B.1.351 first identified in the&nbsp;Republic
of South Africa and has shipped doses to the&nbsp;NIH for a Phase&nbsp;1 clinical trial that will be led and funded by the NIH&#146;s&nbsp;NIAID. The Company also provided an update on its strategy for addressing <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> variants of concern. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Publication of Note: </B>Letter to the editor in the <I>New England Journal of Medicine</I> published
February&nbsp;17, 2021, showed vaccination with the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine produced neutralizing titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the UK and
Republic of South Africa, respectively. The study showed no significant impact on neutralizing titers against the B.1.1.7 variant relative to prior variants. A <FONT STYLE="white-space:nowrap">six-fold</FONT> reduction in neutralizing titers was
observed with the B.1.351 variant relative to prior variants. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Further Clinical Studies of mRNA-1273 </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 2/3 &#147;TeenCOVE&#148; study of mRNA-1273 in adolescents: </B>The Phase 2/3 study of mRNA-1273 in
adolescents ages <FONT STYLE="white-space:nowrap">12-17</FONT> years has completed enrollment of 3,000 participants in the U.S. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 2 &#147;KidCOVE&#148; study of mRNA-1273 in young children:</B> The Phase 2 study of mRNA-1273 in
pediatric population ages 6&nbsp;months to 11 years will start in the near-term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phase 1/2 study of mRNA-1273 in Japan</B>: The Phase 1/2 study of Moderna&#146;s vaccine candidate against <FONT
STYLE="white-space:nowrap">COVID-19</FONT> (mRNA-1273 or <FONT STYLE="white-space:nowrap">TAK-919)</FONT> in Japan, led by Takeda Pharmaceutical Co., Ltd is ongoing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Next-generation vaccine against <FONT STYLE="white-space:nowrap">COVID-19</FONT>
(mRNA-1283):</B><B></B>&nbsp;mRNA-1283 is a next-generation vaccine candidate against <FONT STYLE="white-space:nowrap">COVID-19</FONT> that encodes for the portions of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and <FONT STYLE="white-space:nowrap">N-terminal</FONT> Domain
(NTD).&nbsp;The encoded mRNA-1283 antigen is shorter than mRNA-1273, and is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers. mRNA-1283 is intended to
be evaluated for use as a booster dose for previously vaccinated or infected individuals as well as in a primary series for seronegative individuals. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vaccines requiring complex antigens and against highly prevalent infections </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cytomegalovirus (CMV)</B><B></B><B>&nbsp;vaccine (mRNA-1647): </B>Positive interim data from the Phase 2 study
assessing the safety, reactogenicity, and immunogenicity of different dose levels of mRNA-1647 were presented at Moderna&#146;s annual R&amp;D Day. Based on the interim analysis of the Phase 2 study, the 100 &micro;g dose has been chosen for the
Phase 3 pivotal study, which is expected to begin in 2021. Moderna&nbsp;owns worldwide commercial rights for mRNA-1647.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Epstein-Barr virus (EBV)</B><B></B><B>&nbsp;vaccine (mRNA-1189):</B> mRNA-1189 is a vaccine against EBV
containing five mRNAs that encode viral proteins (gp350, gB, gp42, gH and gL) in EBV. Similar to Moderna&#146;s CMV vaccine (mRNA-1647), the viral proteins in mRNA-1189 are expressed in their native membrane-bound form for recognition by the immune
system. Moderna is planning to begin a Phase 1 study of mRNA-1189 in 2021. There is no approved vaccine for EBV. Moderna&nbsp;owns worldwide commercial rights to mRNA-1189. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Vaccines against respiratory infections </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Human </B><B>metapneumovirus</B><B> (hMPV) and parainfluenza type 3 (PIV3) </B><B>vaccine</B><B>
(mRNA-1653):</B><B></B>&nbsp;Moderna is enrolling<B> </B>seropositive pediatric participants <FONT STYLE="white-space:nowrap">(12-36</FONT> months of age) in the Phase 1 study of hMPV/PIV3 study (mRNA-1653). The first cohort in this study has been
fully enrolled. Moderna&nbsp;owns worldwide commercial rights to mRNA-1653. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Respiratory syncytial virus (RSV) vaccine (mRNA-1345):</B> mRNA-1345 is a vaccine against RSV encoding for a
prefusion F glycoprotein, which elicits a superior neutralizing antibody response compared to the postfusion state. On January&nbsp;11, Moderna announced its plan to amend the protocol to include evaluation of mRNA-1345 in older adults (greater than
50 years), in addition to the pediatric population, who are also at risk of significant RSV disease. In the pediatric population, the first three cohorts of younger adults in the Phase 1 age <FONT STYLE="white-space:nowrap">de-escalation</FONT>
study of mRNA-1345 are fully enrolled. The age range of toddlers in this de-escalation Phase 1 study has been amended to <FONT STYLE="white-space:nowrap">12-59</FONT> months (from <FONT STYLE="white-space:nowrap">12-36</FONT> months). In the older
adult population, the first participant in the Phase 1 study of mRNA-1345 in the adult RSV vaccine has been </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
dosed. The Company also intends to evaluate the potential of combinations of mRNA-1345 with its vaccines against other respiratory pathogens in children and separately in older adults. There is
no approved vaccine for RSV.&nbsp;Moderna&nbsp;owns worldwide commercial rights to mRNA-1345. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Seasonal influenza vaccine (mRNA-1010, mRNA-1020, mRNA-1030):</B>&nbsp;Seasonal flu (type A and type B)
epidemics occur seasonally and vary in severity each year, causing respiratory illnesses and placing substantial burden on healthcare systems. The WHO estimates globally about <FONT STYLE="white-space:nowrap">3,000,000-5,000,000</FONT> severe cases
of flu each year, and <FONT STYLE="white-space:nowrap">290,000-650,000</FONT> <FONT STYLE="white-space:nowrap">flu-related</FONT> respiratory deaths. Approximately 8% of the&nbsp;U.S.&nbsp;population experiences symptoms from flu each year, with <FONT
STYLE="white-space:nowrap">140,000-810,000</FONT> hospitalizations and <FONT STYLE="white-space:nowrap">12,000-61,000</FONT> deaths per year. Peak flu activity is seen in temperate climates from fall to winter and is reflected in increases in
outpatient visits, urgent care visits, and hospitalizations. In the&nbsp;U.S., the estimated average economic burden of seasonal influenza is approximately&nbsp;$11 billion&nbsp;per year. The Company plans to explore potential combination vaccines
against flu, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> RSV and human metapneumovirus (hMPV).<B></B>&nbsp;The Company&#146;s first-generation flu program will evaluate multiple candidates comprising
multiple antigen combinations against the four seasonal viruses recommended by the WHO. The Company expects to begin Phase 1 clinical trials for this program in 2021.</P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Public health vaccines </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Zika virus vaccine (mRNA-1893):</B> Moderna is preparing for a Phase 2 study of mRNA-1893, which is expected
to begin in 2021. mRNA-1893 is being developed in collaboration with BARDA.&nbsp;Moderna&nbsp;owns worldwide commercial rights to mRNA-1893. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>HIV vaccine (mRNA-1644 &amp; mRNA-1574):</B>&nbsp;HIV is the virus responsible for acquired immunodeficiency
syndrome (AIDS), a lifelong, progressive illness with no effective cure. Approximately 38&nbsp;million people worldwide are currently living with HIV with 1.2&nbsp;million in the&nbsp;U.S.&nbsp;Approximately 2&nbsp;million new infections of HIV are
acquired worldwide every year and approximately 690,000 people die annually due to complications from HIV/AIDS. The primary routes of transmission are sexual intercourse and IV drug use, putting young adults at the highest risk of infection. From
2000 to 2015, a total of&nbsp;$562.6 billion&nbsp;globally was spent on care, treatment and prevention of HIV, representing a significant economic burden. mRNA-1644, a collaboration with the&nbsp;International AIDS Vaccine Initiative&nbsp;(IAVI) and
the&nbsp;Bill and Melinda Gates Foundation&nbsp;(BMGF), is a novel approach to HIV vaccine strategy in humans designed to elicit broadly Neutralizing <FONT STYLE="white-space:nowrap">HIV-1</FONT> Antibodies (bNAbs). A Phase 1 study for mRNA-1644
will use iterative human testing to validate the approach and antigens and multiple novel antigens will be used for germline-targeting and immuno-focusing. A second approach, mRNA-1574, is being evaluated in collaboration with the&nbsp;NIH and
includes multiple native-like trimer antigens. The Company expects to begin Phase 1 studies for both mRNA-1644 and mRNA-1574 in 2021.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Nipah virus (NiV) Vaccine (mRNA-1215):</B>&nbsp;NiV is a zoonotic virus transmitted to humans from animals,
contaminated food, or through direct <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">human-to-human</FONT></FONT> transmission and causes a range of illnesses including fatal encephalitis. Severe respiratory and neurologic
complications of NiV have no treatment other than intensive supportive care. The case fatality rate among those infected is estimated at <FONT STYLE="white-space:nowrap">40-75%.</FONT> NiV outbreaks cause significant economic burden to impacted
regions due to loss of human life and interventions to prevent further spread, such as the slaughter of infected animals. NiV has been identified as the cause of isolated outbreaks in&nbsp;India,&nbsp;Bangladesh,&nbsp;Malaysia,
and&nbsp;Singapore&nbsp;since 2000 and is included on the WHO R&amp;D Blueprint list of epidemic threats needing urgent R&amp;D action. mRNA-1215 was <FONT STYLE="white-space:nowrap">co-developed</FONT> by&nbsp;Moderna&nbsp;and the
NIH&#146;s&nbsp;Vaccine Research Center (VRC). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pandemic influenza/H7N9 vaccine (mRNA-1851)</B>: Discussions regarding funding the
Company&#146;s&nbsp;pandemic influenza/H7N9 vaccine program&nbsp;through approval are ongoing. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Systemic Secreted</I></B><I></I><B><I></I></B><I></I><B><I>&nbsp;&amp; Cell Surface
Therapeutics:</I></B><I> In this modality, mRNA is delivered systemically to create proteins that are either secreted or expressed on the cell surface. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Antibody against the chikungunya virus (mRNA-1944):</B> Positive interim data from the Phase 1 study
evaluating escalating doses of mRNA-1944 in the 0.6 mg/kg dose with steroid premedication cohort and two doses of 0.3 mg/kg (without steroid premedication) given one week apart cohort were presented at Moderna&#146;s annual R&amp;D Day in September
and demonstrated dose-dependent increases in levels of antibody against chikungunya. Safety and increased <FONT STYLE="white-space:nowrap">CHKV-IgG</FONT> production in the <FONT STYLE="white-space:nowrap">two-dose</FONT> regimen shows the
platform&#146;s ability for repeat dosing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">IL-2</FONT> (mRNA-6231):</B> mRNA-6231 is an mRNA encoding for a long-acting
tolerizing <FONT STYLE="white-space:nowrap">IL-2.</FONT> This new autoimmune development candidate is designed to preferentially activate and expand the regulatory T cell population. The Company plans to conduct a Phase 1 study of mRNA-6231 in
healthy adult volunteers. mRNA-6231 uses the same LNP formulation as mRNA-1944. The Phase 1 study of mRNA-6231 will be the first clinical demonstration of subcutaneous administration of this delivery technology. Moderna owns worldwide commercial
rights to mRNA-6231. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">PD-L1</FONT> (mRNA-6981):</B> mRNA-6981 is an mRNA encoding for <FONT
STYLE="white-space:nowrap">PD-L1.</FONT> This new autoimmune development candidate is designed to augment cell surface expression of <FONT STYLE="white-space:nowrap">PD-L1</FONT> on myeloid cells to provide
<FONT STYLE="white-space:nowrap">co-inhibitory</FONT> signals to self-reactive lymphocytes. As an initial step to addressing a range of autoimmune indications, the Company intends to pursue <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in a Phase 1 study of mRNA-6981 in type 1 autoimmune hepatitis (AIH), a condition that involves liver inflammation and can lead to cirrhosis and liver failure. mRNA-6981 uses the same LNP
formulation as mRNA-1944. Moderna owns worldwide commercial rights to mRNA-6981. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Relaxin (AZD7970):</B> Moderna has regained all rights to the Relaxin development candidate from AstraZeneca.
Moderna now owns worldwide commercial rights to this development candidate. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exploratory Modalities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Cancer Vaccines:</I></B><I></I><B><I></I></B><I>&nbsp;These programs focus on stimulating a patient&#146;s immune system with antigens derived
from tumor-specific mutations to enable the immune system to elicit a more effective anti-tumor response. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Personalized cancer vaccine (PCV) (mRNA-4157):</B><B></B>&nbsp;The randomized Phase 2 study investigating a 1
mg dose of mRNA-4157 in combination with Merck&#146;s pembrolizumab (KEYTRUDA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), compared to pembrolizumab alone, for the adjuvant treatment of high-risk resected melanoma is ongoing. Phase 1
in multiple cohorts is ongoing. The upsized head&nbsp;&amp; neck cohort is recruiting additional patients. Moderna&nbsp;shares worldwide commercial rights to mRNA-4157 with&nbsp;Merck. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Mutant KRAS vaccine (mRNA-5671 or V941):</B><B></B>&nbsp;The Phase 1 open-label, multi-center study to
evaluate the safety and tolerability of mRNA-5671 both as a monotherapy and in combination with pembrolizumab, led by&nbsp;Merck, is ongoing.&nbsp;Moderna&nbsp;shares worldwide commercial rights to mRNA-5671 with&nbsp;Merck. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Intratumoral Immuno-Oncology</I></B><I></I><B>:</B><I></I><B></B><I>&nbsp;These programs aim to drive anti-cancer T cell responses by injecting
mRNA therapies directly into tumors. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>OX40L (mRNA-2416):</B><B></B>&nbsp;The Phase 1/2 study of mRNA-2416 alone and in combination with durvalumab
(IMFINZI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) is ongoing. The Phase 2 dose expansion study of mRNA-2416 in combination with durvalumab in ovarian cancer patients is enrolling and the first patients have been dosed.<B>
</B>Moderna&nbsp;owns worldwide commercial rights to mRNA-2416. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">OX40L/IL-23/IL-36</FONT></FONT></B><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><B></B><B> (Triplet) (mRNA-2752):</B><B></B>&nbsp;The Phase 1 trial evaluating mRNA-2752 as a single agent and in combination with durvalumab in patients with advanced solid tumor malignancies and lymphoma is
ongoing. mRNA-2752 is an investigational mRNA immuno-oncology therapy that encodes a novel combination of three immunomodulators. Moderna&nbsp;owns worldwide commercial rights to mRNA-2752.<B></B><B>&nbsp;</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">IL-12</FONT> (MEDI1191):</B><B></B>&nbsp;The Phase 1 open-label, multi-center
study of intratumoral injections of MEDI1191 alone and in combination with durvalumab in patients with advanced solid tumors, led by&nbsp;AstraZeneca, is ongoing. MEDI1191 is an mRNA encoding for <FONT STYLE="white-space:nowrap">IL-12,</FONT> a
potent immunomodulatory cytokine. Moderna shares worldwide commercial rights to MEDI1191 with AstraZeneca. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Localized
Regenerative Therapeutics:</I></B><I></I><B><I></I></B><I>&nbsp;Localized production of proteins has the potential to be used as a regenerative medicine for damaged tissues. </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">VEGF-A</FONT> (AZD8601):</B><B></B>&nbsp;The Phase 2a study of AZD8601
VEGF-A,&nbsp;which is being developed for patients with ischemic heart disease&nbsp;undergoing coronary artery bypass grafting (CABG) surgery with moderately impaired systolic function, led by&nbsp;AstraZeneca, is ongoing.&nbsp;Moderna&nbsp;has
licensed worldwide commercial rights to AZD8601 to&nbsp;AstraZeneca. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Systemic Intracellular
Therapeutics:</I></B><I></I><B><I></I></B><I>&nbsp;These programs aim to deliver mRNA into cells within target organs as a therapeutic approach for diseases caused by a missing or defective protein. </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Propionic acidemia (PA) (mRNA-3927): </B>Study <FONT STYLE="white-space:nowrap">start-up</FONT> activities for
the Phase 1/2 study of PA candidate (mRNA-3927) have resumed following <FONT STYLE="white-space:nowrap">COVID-19</FONT> related pause and protocol amendment. mRNA-3927 uses the same LNP formulation as mRNA-1944.&nbsp;Moderna&nbsp;owns worldwide
commercial rights to mRNA-3927.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Methylmalonic acidemia (MMA) (mRNA-3705): </B>Moderna received rare pediatric designation for its next
generation MMA candidate (mRNA-3705). The Company plans to file new IND and CTA applications for mRNA-3705 and will focus development efforts on that candidate going forward. mRNA-3705 uses the same LNP formulation as
mRNA-1944.&nbsp;Moderna&nbsp;owns worldwide commercial rights to mRNA-3705.</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Phenylketonuria (PKU) (mRNA-3283):</B>&nbsp;Individuals with PKU have a deficiency in phenylalanine
hydroxylase (PAH) resulting in a reduced or complete inability to metabolize the essential amino acid phenylalanine into tyrosine. mRNA-3283 encodes human PAH to restore the deficient or defective intracellular enzyme activity in patients with PKU.
mRNA-3283 is in preclinical development. Moderna owns worldwide commercial rights to mRNA-3283. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Glycogen storage disease type 1a (GSD1a) (mRNA-3745):</B><B></B>&nbsp;Individuals with GSD1a have a deficiency
in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">glucose-6-phosphatase</FONT></FONT> resulting in pathological blood glucose imbalance.<B></B>&nbsp;mRNA-3745 is an <FONT STYLE="white-space:nowrap">IV-administered</FONT> mRNA
encoding human G6Pase enzyme, designed to restore the deficient or defective intracellular enzyme activity in patients with GSD1a. mRNA-3745 is in preclinical development. Moderna owns worldwide commercial rights to mRNA-3745. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about each development candidate in Moderna&#146;s pipeline can be found on the investor relations page of its website:
<U>investors.modernatx.com</U>. <B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fourth Quarter and Full Year 2020 Financial Results (Unaudited) </B> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cash Position:</B> Cash, cash equivalents and investments as of December&nbsp;31, 2020 and 2019 were
$5.25&nbsp;billion and $1.26&nbsp;billion, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Net Cash Provided by (Used in) Operating Activities:</B> Net cash provided by operating activities was
$2.03&nbsp;billion for the year ended December&nbsp;31, 2020 compared to net cash used in operating activities of $(459) million for the year ended December&nbsp;31, 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cash Used for Purchases of Property and Equipment:</B> Cash used for purchases of property and equipment was
$67&nbsp;million for the year ended December&nbsp;31, 2020 compared to $32&nbsp;million for the same period in 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Revenue:</B> Total revenue was $571&nbsp;million for the fourth quarter of 2020 compared to $14&nbsp;million
for the fourth quarter of 2019. Total revenue was $803&nbsp;million for the year ended December&nbsp;31, 2020 compared to $60&nbsp;million for the year ended December&nbsp;31, 2019. The increases in both periods in 2020 were driven by increases in
grant revenue and product sales. The increase in grant revenue was primarily due to the BARDA award to accelerate development of our <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine. We began to recognize revenue in December 2020 from our <FONT
STYLE="white-space:nowrap">COVID-19</FONT> vaccine subsequent to its authorization for emergency use by the FDA and Health Canada. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cost of Sales:</B> Costs of sales were $8&nbsp;million, or 4% of Moderna&#146;s product sales, in 2020,
primarily comprised of third-party royalties as the associated inventory costs were expensed previously. If inventory sold during 2020 was valued at cost, Moderna&#146;s cost of sales for 2020 would have been $62&nbsp;million, or 31% of
Moderna&#146;s product sales. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Research and Development Expenses:</B> Research and development expenses were $759&nbsp;million for the fourth
quarter of 2020 compared to $118&nbsp;million for the fourth quarter of 2019. Research and development expenses were $1.37&nbsp;billion for the year ended December&nbsp;31, 2020 compared to $496&nbsp;million for the year ended December&nbsp;31,
2019. The increases in 2020 were largely attributable to mRNA-1273 clinical development, <FONT STYLE="white-space:nowrap">pre-launch</FONT> inventory buildup prior to the emergency use authorization from the FDA and to a lesser extent, an increase
in personnel related costs, primarily driven by an increase in the number of employees supporting our mRNA-1273 development activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Selling, General and Administrative Expenses:</B> Selling, general and administrative expenses were
$79&nbsp;million for the fourth quarter of 2020 compared to $26&nbsp;million for the fourth quarter of 2019. Selling, general and administrative expenses were $188&nbsp;million for the year ended December&nbsp;31, 2020 compared to $110&nbsp;million
for the year ended December&nbsp;31, 2019. The increases in 2020 were mainly due to an increase in personnel costs, and outside services, primarily attributable to increased headcount and mRNA-1273 vaccine candidate commercialization-related
activities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Net Loss:</B> Net loss was $272&nbsp;million for the fourth quarter of 2020 compared to $123&nbsp;million for
the fourth quarter of 2019. Net loss was $747&nbsp;million for the year ended December&nbsp;31, 2020 compared to $514&nbsp;million for the year ended December&nbsp;31, 2019. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Moderna&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Supply Agreements&nbsp;&amp; Regulatory Updates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna&nbsp;has confirmed the following supply agreements of committed orders: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>United States</B>:<B></B>&nbsp;300&nbsp;million doses with options to purchase an additional 200&nbsp;million
doses; the U.S. Food and Drug Administration (FDA) has authorized emergency use in individuals 18 years of age and older </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>European Union</B>: 310&nbsp;million doses with option to purchase an additional 150&nbsp;million doses in
2022; the European Commission&nbsp;has granted a conditional marketing authorization (CMA) for <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Moderna in individuals 18 years of age and
older<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Japan</B>: 50&nbsp;million doses </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Canada</B>: 44&nbsp;million doses; Health Canada&nbsp;authorized
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Moderna for the immunization of people 18 years of age and older under an Interim Order </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Republic of Korea</B>: 40&nbsp;million doses </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>United Kingdom</B>: 17&nbsp;million doses; the UK Medicines and Healthcare products Regulatory Agency (MHRA)
approved the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Moderna for use under Regulation 174, a temporary authorization </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Switzerland</B>: 13.5&nbsp;million doses; Swissmedic, the&nbsp;Swiss Agency for Therapeutic Products,
authorized the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Moderna in&nbsp;Switzerland </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Colombia</B>: 10&nbsp;million doses </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Israel</B>: 6&nbsp;million doses; Israel&#146;s Ministry of Health (MOH) has given authorization to import the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Moderna </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Taiwan</B>: 5&nbsp;million doses </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Singapore</B>:&nbsp;(undisclosed); the&nbsp;Singapore Health Sciences Authority&nbsp;(HSA) approved the
interim authorization of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Moderna for use under the Pandemic Special Access Route (PSAR) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Qatar</B><B></B>&nbsp;(undisclosed); the&nbsp;Qatar Ministry of Public Health issued an emergency use
authorization for the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Moderna </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management Updates </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna&#146;s Chief Medical Officer (CMO),&nbsp;Tal Zaks, M.D., Ph.D., will be leaving the Company in late
September after six years of service. The Company has retained&nbsp;Russell Reynolds&nbsp;to recruit for a new CMO with global and commercial experience as the Company scales up the launch of its <FONT STYLE="white-space:nowrap">COVID-19</FONT>
Vaccine and prepares to file several biologics license applications (BLAs) over the next few years. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I would like to thank Tal for
his tremendous impact on Moderna&#146;s success over the last six years. Tal joined us when we were a <FONT STYLE="white-space:nowrap">pre-clinical</FONT> company. His&nbsp;guidance and&nbsp;contributions were important in
helping&nbsp;Moderna&nbsp;get to where we are today.&nbsp;Through his leadership over the past year in Moderna&#146;s response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, Tal has made a contribution that extends beyond Moderna
to all of society.&nbsp;I have enjoyed having him as my partner and wish him all the best as he embarks on the next leg of his career,&#148; said&nbsp;St&eacute;phane Bancel. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Corinne Le Goff, Pharm.D., M.B.A., joined Moderna as the Company&#146;s first Chief Commercial Officer on
January&nbsp;19, 2021. Dr.&nbsp;Le Goff previously served as SVP and President U.S. Business Organization at Amgen (Nasdaq: AMGN). During her nearly <FONT STYLE="white-space:nowrap">6-year</FONT> tenure at&nbsp;Amgen, she also served as SVP of
the&nbsp;Europe Region&nbsp;and oversaw 48 markets.&nbsp;Dr.&nbsp;Le Goff&nbsp;was actively engaged with the policy community and advocates for innovative, high-quality and affordable healthcare. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Commercial Network </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company started to build a
global commercial network. This infrastructure will enable Moderna&#146;s entire portfolio, which means that Moderna can commercialize its entire pipeline without a large pharmaceutical partner. The Company now has subsidiaries, distributors or
partners in the following geographies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna USA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna Canada </P></TD></TR></TABLE>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>On February</I><I></I><I>&nbsp;18, 2021, the European Commission advised Moderna it had successfully
tendered for the provision of 150</I><I></I><I>&nbsp;million doses of <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Moderna in 2021 and an option to purchase an additional 150</I><I></I><I>&nbsp;million doses in 2022; this tender is
subject to execution of the Purchase Agreement, which is expected February</I><I></I><I>&nbsp;26, 2021, following an opt out period for individual Member States.</I> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna France </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna Germany </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna Italy </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Japan (Partner: Takeda) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna Spain </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna UK </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna Switzerland </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Updates </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Shareholder letter:</B> Moderna&nbsp;CEO&nbsp;St&eacute;phane Bancel&nbsp;published a&nbsp;letter to
shareholders&nbsp;on&nbsp;January 4, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Annual Meeting of Shareholders:</B> The Moderna Annual Meeting of Shareholders will be held on April&nbsp;28,
2021 at 8:00 a.m. ET.&nbsp;The meeting will be held virtually at <U>www.virtualshareholdermeeting.com/MRNA2021</U>. The record date for voting or attendance as a stockholder is 4:00 p.m. ET on March&nbsp;1, 2021. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2021 Financial Considerations </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance Purchase Agreements (APAs)</B>: Already signed APAs for scheduled delivery in 2021, reflecting a total
of $18.4&nbsp;billion in anticipated product sales. Additional discussions ongoing with several governments relating to APAs for scheduled deliveries in 2021 and 2022. Moderna responded to a tender to UNICEF to supply COVAX in 2021 and 2022 and
discussions are ongoing with COVAX/UNICEF. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cost of Sales:</B><B></B>&nbsp;Expected at approximately 20% of product sales for fiscal year 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>2021 Research</B><B></B><B>&nbsp;&amp; Development (R&amp;D) and Selling, General</B><B></B><B>&nbsp;&amp;
Administrative (SG&amp;A) Expenses:</B><B></B>&nbsp;For the first quarter 2021, expect low double-digit percent increase versus adjusted fourth quarter 2020 results of $0.5&nbsp;billion. The fourth quarter 2020 reported expense&nbsp;was
$0.8&nbsp;billion. Adjusted Q4 expense, totaling $0.5&nbsp;billion, excludes $0.3&nbsp;billion of reported expenses, which are now capitalized and expensed through cost of sales, based on our change from a research and development to a commercial
organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Tax Rate:</B><B></B>&nbsp;Effective tax rate expected in the <FONT STYLE="white-space:nowrap">mid-teen</FONT>
percentage level as a result of the forecasted global sales mix and utilization of the accumulated net operating loss carry-forward of $2.3&nbsp;billion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Capital Expenditures: </B><FONT STYLE="white-space:nowrap">$350-400&nbsp;million</FONT> of capital investments
currently planned for 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2021 New Commercial Networks </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2021, the Company plans to further expand its commercial network to enable Moderna&#146;s entire portfolio. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna Australia </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna Japan </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Moderna South Korea </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key 2021&nbsp;Investor and Analyst Event&nbsp;Dates </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Vaccines Day &#150;&nbsp;April 14</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Science Day &#150;&nbsp;May 27 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">R&amp;D Day &#150;&nbsp;September 9 </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Call and Webcast Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna will host
a live conference call and webcast at 8:00 a.m. ET on Thursday, February&nbsp;25, 2021. To access the live conference call, please dial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">866-922-5184</FONT></FONT> (domestic) or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">409-937-8950</FONT></FONT> (international) and refer to conference ID 4066945. A webcast of the call will also be available under &#147;Events and Presentations&#148; in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investors section of the&nbsp;Moderna&nbsp;website at&nbsp;investors.modernatx.com. The archived webcast will be available on Moderna&#146;s website approximately two hours after the conference
call and will be available for one year following the call. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Moderna </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moderna&nbsp;is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct
the body&#146;s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna&#146;s platform builds on continuous advances in
basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates.&nbsp;Moderna&nbsp;is developing therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Headquartered in&nbsp;Cambridge, Mass.,&nbsp;Moderna&nbsp;currently has strategic alliances for development programs with&nbsp;AstraZeneca PLC
and&nbsp;Merck&nbsp;&amp; Co., Inc., as well as the&nbsp;Defense Advanced Research Projects Agency&nbsp;(DARPA), an agency of the&nbsp;U.S. Department of Defense; the&nbsp;Biomedical Advanced Research and Development Authority&nbsp;(BARDA), a
division of the&nbsp;Office of the Assistant Secretary for Preparedness and Response&nbsp;(ASPR) within the&nbsp;U.S. Department of Health and Human Services&nbsp;(HHS) and the&nbsp;Coalition for Epidemic Preparedness
Innovations&nbsp;(CEPI).&nbsp;Moderna&nbsp;has been named a top biopharmaceutical employer by<I>&nbsp;Science</I><I></I>&nbsp;for the past six years. To learn more, visit&nbsp;<U>www.modernatx.com</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MODERNA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited, in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">341,370</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,502</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">528,905</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,173</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,872</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199,872</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,503</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,553</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74,618</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,036</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">570,745</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,055</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">803,395</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,209</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,933</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,933</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">758,860</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117,954</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,370,339</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">496,309</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,990</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,707</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,267</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,620</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">845,783</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143,661</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,566,539</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">605,929</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(275,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(129,606</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(763,144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(545,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,200</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,984</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,715</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,530</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(271,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(123,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(744,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(514,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,473</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(272,485</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(123,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(747,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(514,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares used in net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396,697,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">334,392,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">381,333,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330,802,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MODERNA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF CASH FLOWS DATA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited, in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,246,456</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,262,987</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,336,750</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,589,422</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,775,375</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">414,612</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,561,375</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,174,810</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,026,971</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(458,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used for purchases of property and equipment
<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,448</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(31,554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes $41.7&nbsp;million and $14.6&nbsp;million for the years ended December&nbsp;31, 2020 and 2019,
respectively, related to our Moderna Technology Center facilities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including
statements regarding: the Company&#146;s development of the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine (mRNA-1273); the number of doses of the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine that the Company
anticipates being able to manufacture in 2021 and 2022 and on a quarterly basis, and investments to facilitate that manufacturing; the Company&#146;s efforts to continue developing vaccines against <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
including efforts to develop vaccines against variant strains of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> and for booster doses; the Company&#146;s establishment of additional subsidiaries and
development of its commercial network; the status of developments for programs in the Company&#146;s pipeline, including with respect to the timing, enrollment and potential results of clinical trials; future growth prospects for the Company; the
efficacy of mRNA vaccines and their potential for regulatory approval or authorization; expected timing of execution of the Purchase Agreement by the European Commission for additional vaccine doses; future research and development expenses; sales,
general and administrative expenses; and capital expenditures, as well as other expenses; orders for the Company&#146;s Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine, both inside and outside the U.S., anticipated doses to be
delivered under advance purchase agreements in 2021 and the associated dollar amounts to be received, which should not be construed as expected 2021 revenue; the anticipated cost of sales associated with the Moderna
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine; and the Company&#146;s future tax rate; and personnel recruitment efforts. In some cases, forward-looking statements can be identified by terminology such as &#147;will,&#148;
&#147;may,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;aims,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148;
&#147;continue,&#148; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you
should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna&#146;s control and which could cause actual results to differ
materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use;
the fact that the rapid response technology in use by&nbsp;Moderna&nbsp;is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine observed to date
may change adversely in ongoing analyses of trial data or subsequent to commercialization; the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine may prove less effective against variants of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> virus, or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company may be unsuccessful in developing future versions of its vaccine against these variants; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such
other regulatory agencies may not agree with the Company&#146;s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted;&nbsp;Moderna&nbsp;may
encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine; whether and when any biologics license applications and/or additional
emergency use authorization applications may be filed in various jurisdictions and ultimately approved by regulatory authorities; potential adverse impacts due to the global <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic such as delays in
regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading &#147;Risk
Factors&#148; in Moderna&#146;s most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(SEC) and in subsequent filings made by&nbsp;Moderna&nbsp;with
the&nbsp;SEC, which are available on the SEC&#146;s website at&nbsp;<U>www.sec.gov</U>. Except as required by law,&nbsp;Moderna&nbsp;disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this
press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna&#146;s current expectations and speak only as of the date hereof.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Moderna Contacts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Colleen Hussey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-335-1374</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Colleen.Hussey@modernatx.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lavina Talukdar </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President&nbsp;&amp; Head of
Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-209-5834</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lavina.Talukdar@modernatx.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mrna-20210225.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 2/25/2021 4:40:51 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:mrna="http://www.modernatx.com/20210225"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.modernatx.com/20210225"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210225_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrna-20210225_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mrna-20210225_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 2/25/2021 4:40:51 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mrna-20210225_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 2/25/2021 4:40:51 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mrna-20210225.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>d118084d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mrna-20210225.xsd" xlink:type="simple"/>
    <context id="duration_2021-02-25_to_2021-02-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001682852</identifier>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-02-25_to_2021-02-25">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-02-25_to_2021-02-25"
      id="Hidden_dei_EntityCentralIndexKey">0001682852</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-02-25_to_2021-02-25">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-02-25_to_2021-02-25">2021-02-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-02-25_to_2021-02-25">MODERNA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-02-25_to_2021-02-25">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-02-25_to_2021-02-25">001-38753</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-02-25_to_2021-02-25">81-3467528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-02-25_to_2021-02-25">200 Technology Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-02-25_to_2021-02-25">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-02-25_to_2021-02-25">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-02-25_to_2021-02-25">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-02-25_to_2021-02-25">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-02-25_to_2021-02-25">714-6500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-02-25_to_2021-02-25">false</dei:WrittenCommunications>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-02-25_to_2021-02-25">false</dei:EntityEmergingGrowthCompany>
    <dei:SolicitingMaterial contextRef="duration_2021-02-25_to_2021-02-25">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-02-25_to_2021-02-25">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-02-25_to_2021-02-25">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-02-25_to_2021-02-25">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-02-25_to_2021-02-25">MRNA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-02-25_to_2021-02-25">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139980484674792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 25,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODERNA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3467528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Technology Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">714-6500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MI6J//X7W*+F?&^[_$L4/4$L#!!0    ( /HX65*7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ^CA94APX9>H_ 0
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M 5!+ 0(4 Q0    ( /HX65('04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ^CA94OQ_!>7N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ ^CA94IE<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #Z.%E22=O^XS<$  ! $   &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ ^CA94H.II0/4 0  ,@8   T              ( !>@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #Z.%E2EXJ[',     3 @  "P
M@ %Y#@  7W)E;',O+G)E;'-02P$"% ,4    " #Z.%E2'#AEZC\!   \ @
M#P              @ %B#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M^CA94B0>FZ*M    ^ $  !H              ( !SA   'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ^CA94F60>9(9 0  SP,  !,
M             ( !LQ$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  _1(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d118084d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d118084d8k.htm">d118084d8k.htm</File>
    <File>d118084dex991.htm</File>
    <File>mrna-20210225.xsd</File>
    <File>mrna-20210225_lab.xml</File>
    <File>mrna-20210225_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d118084d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d118084d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrna-20210225_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrna-20210225_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrna-20210225.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mrna",
   "nsuri": "http://www.modernatx.com/20210225",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d118084d8k.htm",
      "contextRef": "duration_2021-02-25_to_2021-02-25",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d118084d8k.htm",
      "contextRef": "duration_2021-02-25_to_2021-02-25",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.modernatx.com//20210225/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-21-055687-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-055687-xbrl.zip
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M-65D%-8B1F_44.><YA0?!![RCGG7EP@*ZH9\H@$*(^4FS50Z4B")UE8SSZ#
MSDZ*T_N)=S^U8_.L1"BC1R-#M1C=AGIKH#L9Q@SQ)H_<Q1<]SB0Q(+!,A5!O
M?IDFV.Q@A#IS_@ H*MS)(PBWU!=4L[,'V)*1#VT/L+H+^B8MDV4GZQ2GL#/!
MY@/VBFD)+(*DGDW)*X[*4X_?^34']L)D;KI]R%W=KU4*!]P_3O7U6$\?#ZB\
MXWX>?]<(#;5(WDA^UX]?X71!,AFJV7R?F5:P[\%D"BV"6NJQ*[06 _.F*R2
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MM@C>Q_FKQ?C[54#<,2"NU^Z&\;Z,%0#6%\E$B0F0@G#4%-&'H"BC((6_\3<
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MP<YP<:M^ KO.- L\G:+6 2/%M@L\@=\:1[!/? ;8E/*"$!_*^>]((GTWQ3Z
MD?$30!'PD1/VA9$+L$Q@;R#$$#<0&Z5SC:A-3TU=H$9\8P0S>(#>D1Z"R!9T
M,A?7..(3- N#S>'J<6.D/9ESX'$ )'Z,A"B)7'+2QN,,X4O<)W)IX'WPO[\
MB#3;4 $+]&'ZIB;+^VR&G37I OC)R$2$=Z1L@K 6;'A.7NJH%YD1LUC(;:UE
M.:#]/%P &;OFL( @"Q2I?"6XUCG;]M;*GVD5AP9!*WRP_^[(#+5_=G%X=-$
M@_O=X/SRZ(7YX][MS</BF>!A?GO6>B8.CMZ].Q\<'AZ?OLD^7YX/#LSG/XX/
MK][^]JS=:OWZC-=S =;2S%/B-_$L!!;4& (^?FRX/I"V>B&O ]?1#QZ:E_N_
MYINZ.IS[L?OK,_%!:]0 E$R[9K< XN/NHM?:<Z\MF* X4/E9/)S2KQJ\HGPX
MXF[$6A'2KQ[%L!5WV+7UFK:K'FA3P<Q@,H!\!'Y]IWTEM'EU_HI@#/]<X#^(
MG16R5\B.9WD^0>3J/.\"T%)G9H17H]W9[B(&22< /=TF=(1'25WP%&*=\J/
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MAY?S]-U"O+)+G032(5WG0W(8II&CL%5&,?C%SB"F/_''VS-L3^-.J3P[%]_
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MQ8GTY"R&WT%[\W7UP:QZ'7\$J6*#98@ZCG;>:4&0)1VC*]BD).][*:@G  J
M2TP7BK-*RZ:H,]:2IG)I[-4S;TJM4V5D2LK1TG.V@T9F9YK#'LX6&)6Z9&J]
M-E_UR#"("U,TCN.18N/#Q<%F95U6$F?)K="\R;CV&S]_NWVZ>\L+TV]O\MW0
M0S<&72TF+@&<!7N@($/6102YYFO)UZJ]S$OFT?Y*4T&491 '1X'3HR&TY+[F
M]YCMT/OQLQT>KPV&:1A [00N*;@'Z,7%/)&99JT&\J<6?LD'S^Z4 [R?=IE&
M(^#1U/H"F#3='2YT,CA^Q7$:$"53W>N!;11!64K4Z1JD2ZQ7Q/<5L[;66>8[
MY=]3QKO+XE4O''6P/ E>RR@;UQ7SNIJ5^[SBXO/E+DU:9#'<9$_<CZD_3OV9
M<:UK9K[;T^Y"L=+]L;:Y/V82']'^UJEX_EA7>,Q\[C"XR5AK-;?$=/S\H[Z@
M188Y7B"%XT/MDKMSD,VN\Z%)R;D)\B%;S:X>80/?QN#\P@$VQ1AV@1%_197%
M07)@E0P][&=<3,,M7*HPH>K8I%T":8-FSVX=+FO9R,O2%V/ A;MQ<OY8"D>2
MU<EGY9O?7Z4N^]O?/S2.QV^,MLC%\Y+<'[I\" !Q S>0YPB, <=\JF<7LP@/
MX7#QADT&H:%+)@Y?N F!E2$([A/'%6^J>!/W!EJ&CL?OLKH FD-M=;KM8HXY
M?B8_!]\6F\LJYWX*:(!A.#X)/.!DJSE2<>;,QKY"B8[Q 9DF =\@NZ,QFUOV
MY6)..UV-Y5K>E%Y"G@ @;)#DIMD%4!FFTZ!?XHH%>IY@<T?N!3I"@;;OO*+&
M</'K-0ZPSW2.\'7@I<#I\GO^]!SY5?CB[U2)=Z?G=(4N*ST4Y_R[62P LVA*
MX]W-,YJS/(2<2VJG?YP.[321OL(NXW/5"2CO*->:0$]2]L1';\TLO[1W9SBU
M7IN+I^+:*GY4\:,OY$?GAXUW[3F&M+M39DCP^4Z&M$+Z&TWQY9Q'IF-^H& >
M&.-!T]?#=@OO3&<P+^A7.*;V U+1D!7JP-@!H-W$'6()XEF6$ FKE3Q2K+Q1
M@\H-H,KIS:;A)+!GB<*4Q)@[_;B4808Z7DC[RTMR%QS"!2AAB1#MSIUKEY,G
M@8=I%*<KUU"_]]@ %,&H ?^CNMUA,N?,ON<R,2.,SSFQ[>(6)@KS!1,XV8W!
M\=M-CG3ZYG(0U9[W@:%? UX3DR0'BIQ.99*[S%'GE(01MAM%DR!V.3K'+XRD
MZU%(/E_)+5E0K]TM#)8RXOF\%IRBXL,5'UYV\9";WVX,_G>XO;O=FLORPKA!
MM*[6N7G_&@&TO!(F:\5DP>@KH/9C=!X]HD1<5B#S?I_+&I^NI\-GT5]V(+%G
MP8(6GW=XVK(<W%CE#6DIX"_HCJ;+;(=XO$Z=-E:G9I'L2M.=ADR& 9PF]FP"
MQD7>BG0:1'E[C2EHG%D@2_E44RLO#&$&S/,P)+>9S7.8<)H&#9K=-*W\;A4/
MNQ4] 1L+4XZP^1DR""2,+')R?O!A4^N/O79_>T$- S2S0*UQ@BD-4,YB!;&/
M,>.QH8UVO3;5GC2C5>"PG "39^03E9P ._MHJ"C$PBD!K#&=RJ'8^/WHSZN+
M]X>#EY?O%Z#Q3O_7/6Q\1X7X&N3-?\%G ,P8C@!>>@5*2O'6=7E\"=:XLK)J
M@MAS\!I#U(7P^HB2TAJ4D89>.0H:3X&A^P#H4FE.K4QA]DXA#U]?6RX^B)!,
MPYC ",:P4W3J@P#XF%5<H'S[*'49J'D/,<UYXKEB"]AS4:VF]=!A(/1U]!:/
MH"HN6K&093UG4VI"]_O%X'(NZ-K?VFYC-.C#;J]]!_,PQD80*K_AR2&V "0Z
M:7"(4;,2+.M8N@M;:#]+_C+CWC6,A::FC#8J_#C%Y"(*AAEW]6V64^("I@QO
M@12L(KTN2'!X *71ZCZ#THI:66?M>M$Q-LXCE0&;S')>XYEODS?KMH[T8DYE
MND=7DBZI*DZ4*29:TF@WHE%0J/V\Z_^EM">4/!-\;*@H<D(774A&]187&E<Z
M3<60YAG2V?_U6N\T"^KTVEOWLYY;Y<3Q%58"[F053AHA,P(^4:]M')^\/C[]
MW_$7:".W% &C1Y&N1!YX70[FUCKO7QU=W>=>1T:Y,VI"J>Q4UL_:5/?0SU!F
M(>6^<:T"*FJ%4/R\ZT*XXA\I^Z7_XV>_5/SP^^>'7YX!31SU.08;N_AO5CHH
M^\_^O/,9/S5>#TZ.W_WYXO+/D_VS=P3*5G?/O),5"!4;5Q&:18FQ-3O;_<X2
M=9%;;!;2.;(76=]#C[M'!9GT/9[E?#)C>KH?]+6DJEHQ:(0.*QMP%D@=,F\+
MS1$ ,OGJM8R#YVMQ=5 @LX/)4N-4*]:O JU?":.=EBK:FSLZQ:53R!&+7_$(
MT\#AH.R\X;<Z5X:5-O/C,&A,E0@KTZ_B+%^8&='.4R-.C@Z/V^W=S[4%"[78
MW**IHBT&?2/"3+*R"K<:\<=EB[#@FB_9A?GT]P=7E\',U(R@DH-4N&*>WF?"
MGB7!1VHF;D(#JYF@V1)IL\4@P\/B NNW0-\%-KLBL9FIJ6T!*NA=>:SWN.NS
MH8KY98 >6?KJ1-_AR,N"T.TXOO!'0B0J+F&J^\W2&3IR"NP!,,.-XU05C-"*
M-U:\<57>^.'HS>O&(&..@_\=[FRU[N>-'9G;@/KY>HW'T1>*LEH1\R4@J-M)
MB<NYL3VAC/.)PE1378&3A\$VY1%Q-& A$6@M>!<-6\3,@ .&,H[%.)(CTKPV
M#@;[;S8Q>6.,/]/04^1'NGC<-)2N22</L);**/5MKB>Y"D-=X&B;8-=?&$GY
M<>FR^T)FI\$$?]Z:YYNSNRSGGSQOZ H#UA[=G;:_>G32>-PX+4UKG.@UXZ08
M/"3,Y:";S"*(QIBN1SPOR:?.+TT3RV/TT'?WJ-"/%'3O$7  ?U<F\J@Y;,44
M*Z9X.]P8!2&0/B*73=<2I=@X'QC#K[O;,7UA+HG-+>\8CKTD&VF8:4M<&4U?
M::?Z"(O\?.>#0JI%86YV>($*E4Z)97I><+-2'NY\7S)=PPXX;JK+761UF*G"
M+X81M:&($S\DM75IO1ZZ)7R'K8>357?X*R*]/Z"GDLG,FZ+]5"+4DY.<4K=;
M?4VIQO:(E*TPGT5$U*@MJ]_-Z9ZZ1AUV5J,KR)^2>JU0O Z&ODV1.,<=>>4C
M%\M?P"Z.3P^)O ZN!BBO"K5J3,40'(8>X09TE+93S(I2HQ'7$-?)BODR6/^!
M7V]DY#0+HRVC5HY<K4BN]WAF<+**6BMJ7=(55_DS[Z-* C^-2)[^_CXCTZP_
M9UZ+P#0S)$4=GF69)T5>0XL<(C2J!'ISL0_19.9$P2?X(L:TH,';31*2'AD
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MM'W'S2!__E)SZ(98S([J%J-G=D1M\[).F]=T$FQJD<J'_(2" PA9-8P!!U[
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M%8N>1TI%%D)D9T_$TM4G=IG\6TD;M,J]$#!1B7T\4*]9Y8E6$L](O /0[GQ
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MR^4.K\Q:KKD<^X4T6',9!*'#-W)1.Z!^8GA#DBZ;W+[P0GF@*]UL:=[:3L4
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M AL$U8G,1U)I'#>.TI!A#^_B,3IHP;A#MK%(>\MLD"_E>WL@N!6=$@MQE'*
M<4.7H&''PG-MM'X0_O G-_?!9Y^7K#;8-W#E,<&*9'_1:"R_JY$9Q0W=4D5L
M#,#L_@N@$J.R:&80H#:03ND51"GH T6DX&E0TN\5K%DM8% 02K204:'2%OC8
M"X;PQ(/!!5CIJ*EK9WB5G2XZ1K,%@<7CJAMK[J3)V"R;\Y8Y>Y")>,J(,>;8
MK6P#+(5B5 (G"K59&Y6Q>!:#ZA/K6[P&6XQ<TCM4@.#!=&;,(%2P-#6BFJ3U
MPH*FA)1A Y)E%B2.!9.2+X/5\PMXLUY[S6J45M%A[7-*X11M.S0905[_-_.4
M7:@03"G<R&MT3RZ%?[O5^*^!/:.*X1%,:V@.%SV@N)^C3UK!R)T+_/#&Y='!
MIO;2%=4)S2S@M)P[]"R<E+0V_@CC6 6M6%Y+UR.S@[5T ;\;,-RH88RL529:
M\KY_=7-STXR5W1P'UR^?OW_5Q 4KD-42&=W?J1LQ?GORQEJP%#AIVT,[C0B4
M##L^]LAHCZ[6[$C=#!T.!=//6(:7\'"V@@G$9(F&3;U6MFRT\PNM>C+??1!6
MKH_^9J)MRXBADOO,B(P;L(.,JG[/(LC:D&0%W$(M..W(^'SL).=%(@Y!)X 7
MD%-D"AKJG0+5^&#4O,?)O[8X@V'%!PA&NQ!=6*PCK"6X@-."A2U??)50QD'@
M>6@'O4W!3)N)QU4F7QT"02"KL0"B$7 //$ZD[-3/9,DC7QI;[LY>^L!6>[O1
M[?8;[2ZVP2GI^(^^^/?FP)I\8/]ORAB:?&J"XB20!]U]A!0!7@=^'E-@)$ 3
M^VO@Z#M49:6XDE[ZT9'18R/II?)=X' ?0$L2Y\ LR?&GH_]R&NZ)MR!"@2/5
M:P8.( J] OH^XMK6@[V=UFZCO]/]!MC+1]DT1WD7^GZ/AG'W?L,8".7L\$_X
M\NW5R;M7_Q]02P,$%     @ ^CA94J$8'\QE P  *0P  !$   !M<FYA+3(P
M,C$P,C(U+GAS9+U6WV_;-A!^+]#_X:JG#9A$R:D76(A3=$L#!$BSPDV'O14T
M13O$*%(CJ<3^[W>D)%MV;-=.AN4E-.^^N^]^4A<?%J6$1VZLT&H<94D: 5=,
M%T+-QU%M8VJ9$-&'R[=O+M[%,5Q=W]Q!# _.538GY.GI*2EF0EDM:X<6;,)T
M22".._W?[[_!GXWU'"9<<FHY#-)!&I_#;[601>Y_9%F6)ED?9CCU]J"@CN<P
M((,A0<4,WN?OTWR8P9?/\(E:QXV">U'R/E172R/F#PY^8C]# %UII;B4? G7
M0E'%!)7PM6/\"]PHEL!'*6'B819I6FX>>9&T5A>VR"U[X"5]^P8 \Z5LKM!D
M78XCGX@V#XNID8DV<U(X0]RRX@258M3B1K"H!_TQ[AD&"^$E=@6<43L-H$Z"
MZ<E&<9K%9UD/5QI%-YR5NL"<4;<(A?+920>#80]1<+$"!&:6LV2N'PD*=OOP
M6F)W1(,T/2/8'0Z3SGL0*=3?!Q!>/,5&Z3MY!GDZ"X!L-!J1(-VB5+C-.%KK
M0]((>]I6L-TAH\"'G/5"ILX9,:T=O]:FO.(S6DOT4ZM_:BK%3/ B:&&?EURY
M#9U-#4?-G+L[6G);4<9/JQ$VY*Y48'09^>OS[=?0J]&E!P"$]A5EI8V#IHMO
M-0O#=: "_E?<%2[V5W$VP!PD:"P"M9/VGJH#>361KA]>1&353$<3L?M:WQ_B
M]0SLXW!H;%Z<C>WEX',Q\KG(?CTJ%\^6RW_ 1*N[UY+I;<A3".T<4W^(U_-Z
M5'FV1OSE/:*H8&$)GS='3^3\!")K_&L[I;?D?%V&!]UO;\76:_!)E=(N..HS
MH54EU$RW5WCI!RSOIFS"9Q"V<4X-,UKRPSN;5$97W#B!#]AZ4!L##X;/QI%_
MP>)N!WZ7=)K@#NQ4GCG8''TO)@CA\G9-K\,ZX3SXUHO!R_%+@,J5:=^>X\AB
MWF5O=?S/X5:&GQHN0BP^/:%L^Z/^TM,Z.7COYQXUP!^^36X./%ZKUXLXNM!*
ME\N&Y95FM7\AN_\?5?%)(;?E#;:6*0.O" 0^<Q-4_WZ4^HIEQ[/@^&4J0O]F
MJ?_##]?.0O](50&-.>C9NR#;1K;MUY87?ZC+<&94LEJNLMZ"6XU#P.UZ'8]<
M,]N/:V^[BG5S3+8'N;WI#WQSU2P<_/DO4$L#!!0    ( /HX65))E#,T708
M $A$   5    ;7)N82TR,#(Q,#(R-5]L86(N>&ULS9QO3]M($,;?5^IWF,N]
MN9/J)*:M3D2E%1>@0D<!07IWNM.I<NPE69VS$^TZD'S[V_6?XI"U8^/QF1>E
MQIYY9A[S&[.V'#Y\6B]"N&=2<11'/;<_[ $3/@9<S(YZ*^5XRN>\!RKR1."%
M*-A1;\-4[]/'UZ\^_. X<')V?@D.S*-HJ4:#P</#0S^XXT)AN(JTI.K[N!B
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M=\$%<^L-A56@TX$HLX1[ IL/0J$H[1"D^F^R#3"5X$I0K6Q:LV$9@&=X(1^
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M8RBNJ;MZU-?5K +-1R?:Z]MZ?2UO/K_C0F^9OX"1[N+)WX'0>_X#4$L#!!0
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M,#@T9#AK+FAT;5!+ 0(4 Q0    ( /HX65+2;HV /DP  *D? @ 1
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64$L%!@     %  4 0 $  *YJ      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
